Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - HIV

Volume 3

eBook: US $100 Special Offer (PDF + Printed Copy): US $169
Printed Copy: US $119
Library License: US $400
ISSN: 2468-0397 (Print)
ISSN: 2352-5916 (Online)
ISBN: 978-1-68108-230-1 (Print)
ISBN: 978-1-68108-229-5 (Online)
Year of Publication: 2016
DOI: 10.2174/97816810822951160301


Frontiers in Clinical Drug Research – HIV is an eBook series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of acquired immune deficiency syndrome (AIDS) and other disorders associated with human immunodeficiency virus (HIV) infection. The scope of the eBook series covers a range of topics including the medicinal chemistry and pharmacology of natural and synthetic drugs employed in the treatment of AIDS (including HAART) and resulting complications, and the virology and immunological study of HIV and related viruses. Frontiers in Clinical Drug Research – HIV is a valuable resource for pharmaceutical scientists, clinicians and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in HIV/AIDS research.

The third volume of this series features 5 chapters that cover a variety of topics including:

  • - Studies of HPV infections in HIV positive people
  • - Allosteric Integrase Inhibitors
  • - HAART
  • - Drugs targeting various types HIV-1 enzymes


The book series, “Frontiers in Clinical Drug Research-HIV” presents important recent developments in the form of cutting edge reviews written by the authorities in the field. The chapters in this 3rd volume are mainly focused on Human papillomavirus (HPV) infections, different HIV-1 inhibitors (integrase inhibitors, protease inhibitors, entry inhibitors and reverse transcriptase inhibitors), Highly Active Antiretroviral Therapy (HAART) and blockage of HIV-1 replication.

Anna Rosa Garbuglia in Chapter 1 discusses a common sexually transmitted disease, Human papillomavirus (HPV) infection that leads to about 250,000 deaths each year. Ashton et al., in chapter 2 discuss the structure, function and mechanism of HIV-1 integrase inhibitors. Highly active antiretroviral therapy (HAART) uses multiple drugs that can act on special viral targets. Chapter 3 by Silpi Basak describes the importance of this therapy that stops the replication of HIV and reduces HIV related deaths, illness and hospitalization by 60-80%.

Chapters 4 to 8 by Liu & Kong provide novel insights into the design of individual anti-HIV strategies on treatments and minimizing side effects for clinical development. These chapters include current progress and challenges in the development of entry inhibitors, prospects of reverse transcriptase inhibitors, targets and clinical applications of integrase inhibitors, outlook of proteinase inhibitors and blocking HIV-1 replication by targeting the Tat-hijacked transcriptional machinery.

I am grateful to all the eminent scientists for their excellent contributions. I also express my gratitude to the editorial staff, particularly Mr. Mahmood Alam (Director Publication), Mr. Shehzad Naqvi (Senior Manager Publications) and Ms. Fariya Zulfiqar (Assistant Manager Publications) for their hard work and persistent efforts.

Prof. Atta-ur-Rahman, FRS
Kings College
University of Cambridge